Results 11 to 20 of about 8,244 (227)

Safety and Efficacy of Low-Dose Eptifibatide for Tandem Occlusions in Acute Ischemic Stroke [PDF]

Neurology International
Objectives: The optimal treatment strategy for ischemic stroke in patients presenting with tandem occlusions of the internal carotid artery remains controversial.
Paweł Latacz, Tadeusz Popiela, Paweł Brzegowy, Bartłomiej Lasocha, Krzysztof Kwiecień, Marian Simka   +5 more
doaj   +3 more sources

Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage

Case Reports in Critical Care, 2021
Background. Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests antibody-dependent
Gregory Byrd, Sabina Custovic, David Byrd, Deanna Ingrassia Miano, Jasdeep Bathla, Antonious Attallah   +5 more
doaj   +2 more sources

Immediate outcomes of eptifibatide therapy during intracoronary stent implantation

Advanced Biomedical Research, 2016
Background: The objective of the present study was to assess the major immediate outcomes of eptifibatide therapy during intracoronary stent implantation.
Hooman Shariati, Hamid Sanei, Ali Pourmoghadas, Leila Salehizadeh, Afshin Amirpour   +4 more
doaj   +2 more sources

Relation of Level of Platelet Inhibition after Eptifibatide with Major Cardiovascular Events in ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Majalah Kardiologi Indonesia, 2015
Background: Eptifibatide, an inhibitor of glycoprotein IIb/IIIa administered as adjunctive therapy to reperfusion therapy Primary PCI in STEMI patients.
Elisa Feriyanti Pakpahan, Sunarya Soerianata, Nur Haryono   +2 more
doaj   +3 more sources

Eptifibatide-induced acute profound thrombocytopenia in a patient with left main artery plaque rupture complicated by cardiogenic shock and gastrointestinal bleeding

Journal of Clinical and Preventive Cardiology, 2021
Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen and adhesion proteins such as fibronectin, vitronectin, and von Willebrand ...
Savvy Nandal, William Van Gaal, Francis A Ponnuthurai   +2 more
doaj   +2 more sources

There is no difference in safety and efficacy with Tirofiban or Eptifibatide for patients undergoing treatment of large vessel occlusion and underlying intracranial atherosclerosis

Interdisciplinary Neurosurgery, 2021
Background: Glycoprotein IIb/IIIa inhibitor use in acute ischemic stroke (AIS) during mechanical thrombectomy (MT) and acute stenting and angioplasty is a topic consistently debated due to concerns over safety and efficacy.
Hari Movva, Rani Rabah, Wondwossen Tekle, Alexandros Georgiadis, Laurie Preston, Hari Kotta, Ameer E. Hassan   +6 more
doaj   +2 more sources

CLINICAL CASE HISTORY OF EPTIFIBATIDE USE DURING CORONARY INTERVENTION IN PATIENT WITH CORONARY FAILURE

Рациональная фармакотерапия в кардиологии, 2015
Clinical case history of endovascular intervention in infarct related coronary artery with 4 sirolimus-eluting stents implantation and their further thrombosis during early postoperative period is described.
K. A. Kireev, A. V. Krasnopeev, T. S. Kireeva   +2 more
doaj   +3 more sources

Eptifibatide bolus dose postductal stenting intervention: A single-center experience [PDF]

Annals of Pediatric Cardiology
Objectives: Stent thrombosis, a potential complication of ductal stenting, is associated with high mortality. This is a catastrophic complication, which can occur acutely (within 24 h), subacutely (within 30 days), or late (≥30 days) after stent ...
Rishika Mehta, Amitabha Chattopadhyay, Aritra Mukherji, Sanjiban Ghosh, Jayita Nandy Das, Pushpanjali Gupta   +5 more
doaj   +2 more sources

Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background After a loading dose of ticagrelor, the rate of high on‐treatment platelet reactivity remains elevated, which increases periprocedural myocardial infarction and injury.
Moazez J. Marian, Hussein Abu Daya, Arka Chatterjee, Firas Al Solaiman, Mark F. Sasse, William S. Fonbah, Raymond W. Workman, Brittany E. Johnson, Sarah E. Carlson, Brigitta C. Brott, Sumanth D. Prabhu, Massoud A. Leesar   +11 more
doaj   +2 more sources

Eptifibatide and abciximab inhibit insulin-induced focal adhesion formation and proliferative responses in human aortic smooth muscle cells

Cardiovascular Diabetology, 2008
Background The use of abciximab (c7E3 Fab) or eptifibatide improves clinical outcomes in diabetics undergoing percutaneous coronary intervention. These β3 integrin inhibitors antagonize fibrinogen binding to αIIbβ3 integrins on platelets and ligand ...
Huang Jianhua, Zhao Renyi, Pathak Alokkumar, Stouffer George A   +3 more
doaj   +2 more sources